Skip to Navigation Skip to Search Skip to Content
Search All Centers

What Factors Play a Role in Finding a Suitable Myeloma Therapy?

Read Transcript Download/Print Transcript

Published on August 21, 2018

Each multiple myeloma patient’s course of treatment is determined by a number of factors specific to the individual. What goes into consideration before making treatment decisions? How do genetic mutations influence myeloma care? Myeloma expert Dr. Joshua Richter, from Mount Sinai School of Medicine, explains what disease characteristics your healthcare team will examine before developing a treatment plan. Watch now to learn more.

This is a Patient Empowerment Network program produced by Patient Power. We thank AbbVie, Inc., Celgene Corporation, and Takeda Oncology for their support.

Featuring

Sponsors

Patient Empowerment Network

You might also like

Transcript | What Factors Play a Role in Finding a Suitable Myeloma Therapy?

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That's how you’ll get care that's most appropriate for you.

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.

Jack Aiello:

Treatment factors means have we given a previous line of therapy and did it cause toxicity.  So if we've given drug A and the patient had horrible neuropathy I would not utilize that drug and may think twice about drugs that are similar.  Host factors are things such as the patient's age, their frailty, other co?morbidities that they have that may affect the choice of drugs that we give.  And disease factors are crucial.  How quickly is the disease progressing?  Is it taking other forms such as forming tumors such as plasma cytomas?  Is it involving other areas of the body?  

And as Dr. Krishnan pointed out, we're starting to understand that certain drugs may have better efficacy in certain subgroups of patients.  So, for example, venetoclax (Venclexta) in patients with that (11;14) translocation or something called Bcl-2 overexpression, we may utilize a drug like that in a patient earlier rather than later because that—realistically, they'll have a higher response rate.  

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.

You might also like